Ghadjar Pirus, Coupland Sarah Ellen, Na Il-Kang, Noutsias Michel, Letsch Anne, Stroux Andrea, Bauer Sandra, Buhr Heinz J, Thiel Eckhard, Scheibenbogen Carmen, Keilholz Ulrich
Department of Hematology, Institute for Medical Informatics, Biometry, and Clinical Epidemiology, Charité, Campus Benjamin Franklin, Berlin, Germany.
J Clin Oncol. 2006 Apr 20;24(12):1910-6. doi: 10.1200/JCO.2005.04.1822.
The liver is the primary organ of metastasis in colorectal cancer (CRC). Chemokine receptor CCR6 is expressed on a subset of T cells and is associated with their migration into the liver. This study was performed to analyze a possible association between CCR6 expressed by primary CRC and liver metastases.
CCR6 expression levels were evaluated by immunohistology in 64 CRC primary tumor specimens. Twenty-four of 64 patients had synchronous liver metastases. Evaluation of immunostaining was performed semiquantitatively by visual assessment and quantitatively by digital image analysis (DIA). Multiple logistic regression analysis was performed to assess relevant parameters for liver metastases.
CCR6 expression was verified in all 64 primary tumor specimens with considerable variations in intensity; 21 tumors (33%) demonstrated weak CCR6 staining, 32 (50%) demonstrated intermediate staining, and 11 (17%) demonstrated strong staining. Quantitative assessment by DIA showed an up to 5-log difference in CCR6 values. CCR6 staining was significantly stronger in tumor cells compared with adjacent colon epithelial cells (P < .0005). Multiple logistic regression analysis, controlling for age, sex, tumor stage, nodal status, pathologic grade, and preoperative carcinoembryonic antigen levels, revealed that CCR6 staining in the primary tumor was independently associated with the presence of liver metastases (odds ratio = 2.1; P = .002).
The association between expression level of CCR6 in primary CRC and synchronous liver metastases suggests that CCR6 and its ligand may be involved in the metastatic spread to the liver. Therefore, CCR6 may be a potential target for specific therapeutic interventions.
肝脏是结直肠癌(CRC)转移的主要器官。趋化因子受体CCR6在一部分T细胞上表达,并与这些T细胞向肝脏的迁移有关。本研究旨在分析原发性CRC中表达的CCR6与肝转移之间可能存在的关联。
通过免疫组织学方法评估了64例CRC原发肿瘤标本中的CCR6表达水平。64例患者中有24例发生了同时性肝转移。免疫染色评估通过视觉评估进行半定量,通过数字图像分析(DIA)进行定量。进行多因素逻辑回归分析以评估肝转移的相关参数。
在所有64例原发肿瘤标本中均证实有CCR6表达,强度存在显著差异;21个肿瘤(33%)显示CCR6染色较弱,32个(50%)显示中度染色,11个(17%)显示强染色。DIA定量评估显示CCR6值相差高达5个对数。与相邻结肠上皮细胞相比,肿瘤细胞中的CCR6染色明显更强(P <.0005)。多因素逻辑回归分析在控制了年龄、性别、肿瘤分期、淋巴结状态、病理分级和术前癌胚抗原水平后,显示原发肿瘤中的CCR6染色与肝转移的存在独立相关(比值比 = 2.1;P =.002)。
原发性CRC中CCR6表达水平与同时性肝转移之间的关联表明,CCR6及其配体可能参与了向肝脏的转移扩散。因此,CCR6可能是特异性治疗干预的潜在靶点。